Given the differential expression of PSMA between PCa and normal tissues, small molecule PSMA targeted radiotherapeutics have been developed for prostate cancer, such as the FDA approved 177Lu PSMA-617 (Pluvicto®) and the promising non-FDA approved 177Lu PSMA I&T. This evidence concerns the gene FOLH1 and prostate carcinoma.